Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: Do the math

Journal of the American College of Cardiology

Volumn 58, Issue 5, 2011, Pages 457-463

  Ramjee, Vimal ^a   Sperling, Laurence S ^b   Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

apolipoprotein; cardiovascular risk; coronary heart disease; cost effectiveness; non HDL; risk stratification

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACCURACY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG TARGETING; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNONEPHELOMETRY; ISCHEMIC HEART DISEASE; MATHEMATICAL COMPUTING; NEPHELOMETRY; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; LIPOPROTEINS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 79960603473     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.05.009     Document Type: Review

References (53)

1. Browning R. Andrea del Sarto ("The Faultless Painter"). 1855.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. D. Lloyd-Jones, R.J. Adams, and T.M. Brown Executive summary: heart disease and stroke statistics2010 update: a report from the American Heart Association Circulation 121 2010 948 954
4. T.R. Pedersen, A.G. Olsson, and O. Faergeman Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460 (Pubitemid 28191300)
5. S. Mora Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use Circulation 119 2009 2396 2404
6. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
7. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
8. P.S. Sever, B. Dahlof, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
9. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
10. C. Baigent, L. Blackwell Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
11. Y. Cui, R.S. Blumenthal, and J.A. Flaws Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1419 (Pubitemid 32681162)
12. M.R. Hoenig Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target Vasc Health Risk Manag 4 2008 143 156 (Pubitemid 351460855)
13. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 19992008 JAMA 303 2010 235 241
14. C.D. Gardner, M.A. Winkleby, and S.P. Fortmann Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 19881994) Am J Cardiol 86 2000 299 304 (Pubitemid 30462225)
15. A.H. Mokdad, E.S. Ford, and B.A. Bowman Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 JAMA 289 2003 76 79 (Pubitemid 36026281)
16. M. Okubo, A. Horinishi, and M. Saito A novel complex deletion-insertion mutation mediated by Alu repetitive elements leads to lipoprotein lipase deficiency Mol Genet Metab 92 2007 229 233 (Pubitemid 47513561)
17. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524 (Pubitemid 351470037)
18. H. Scharnagl, M. Nauck, H. Wieland, and W. Marz The Friedewald formula underestimates LDL cholesterol at low concentrations Clin Chem Lab Med 39 2001 426 431 (Pubitemid 32529925)
19. E.A. Stein, A. Sniderman, and P. Laskarzewski Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 96 2005 36K 43 discussion 34K5
20. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
21. M.J. Blaha, R.S. Blumenthal, E.A. Brinton, T.A. Jacobson National Lipid Association Taskforce on Non-HDL Cholesterol The importance of non-HDL cholesterol reporting in lipid management J Clin Lipidol 2 2008 267 273
22. K.C. Maki, R. Galant, and M.H. Davidson Non-high-density lipoprotein cholesterol: the forgotten therapeutic target Am J Cardiol 96 2005 59K 64 discussion 34K5
23. J.J. Kastelein, W.A. van der Steeg, and I. Holme Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
24. W. Lu, H.E. Resnick, and K.A. Jablonski Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study Diabetes Care 26 2003 16 23 (Pubitemid 36928989)
25. V. Bittner, R. Hardison, and S.F. Kelsey Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 106 2002 2537 2542 (Pubitemid 35340688)
26. P.H. Frost, B.R. Davis, and A.J. Burlando Serum lipids and incidence of coronary heart disease Findings from the Systolic Hypertension in the Elderly Program (SHEP) Circulation 94 1996 2381 2388 (Pubitemid 26403562)
27. P.M. Ridker, N. Rifai, N.R. Cook, G. Bradwin, and J.E. Buring Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 2005 326 333 (Pubitemid 41043776)
28. T.R. Pedersen, O. Faergeman, and J.J. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445 (Pubitemid 41627921)
29. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
30. B.J. Arsenault, J.S. Rana, and E.S. Stroes Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women J Am Coll Cardiol 55 2009 35 41
31. E. Di Angelantonio, N. Sarwar, P. Perry Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
32. J. Liu, C. Sempos, R.P. Donahue, J. Dorn, M. Trevisan, and S.M. Grundy Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes Diabetes Care 28 2005 1916 1921 (Pubitemid 41060963)
33. A.M. Gotto Jr, E. Whitney, and E.A. Stein Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484 (Pubitemid 30080860)
34. G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033 (Pubitemid 34084825)
35. S. Yusuf, S. Hawken, and S. Ounpuu Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952 (Pubitemid 39208455)
36. J.H. Contois, J.P. McConnell, and A.A. Sethi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
37. B. Lamarche, J.P. Despres, S. Moorjani, B. Cantin, G.R. Dagenais, and P.J. Lupien Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study) Am J Cardiol 75 1995 1189 1195
38. B. Lamarche, S. Moorjani, and P.J. Lupien Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study Circulation 94 1996 273 278 (Pubitemid 26266109)
39. J.E. van Lennep, H.T. Westerveld, H.W. van Lennep, A.H. Zwinderman, D.W. Erkelens, and E.E. van der Wall Apolipoprotein concentrations during treatment and recurrent coronary artery disease events Arterioscler Thromb Vasc Biol 20 2000 2408 2413
40. T. Pischon, C.J. Girman, F.M. Sacks, N. Rifai, M.J. Stampfer, and E.B. Rimm Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 112 2005 3375 3383 (Pubitemid 43739551)
41. E. Ingelsson, E.J. Schaefer, and J.H. Contois Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 298 2007 776 785 (Pubitemid 47263160)
42. A. Simon, G. Chironi, J. Gariepy, M. Del Pino, and J. Levenson Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men Atherosclerosis 179 2005 339 344 (Pubitemid 40364629)
43. C.M. Ballantyne, T.C. Andrews, J.A. Hsia, J.H. Kramer, C. Shear ACCESS Study Group Atorvastatin Comparative Cholesterol Efficacy and Safety Study Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels Am J Cardiol 88 2001 265 269 (Pubitemid 32721953)
44. N.R. Cook Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve Clin Chem 54 2008 17 23 (Pubitemid 351182592)
45. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
46. M.G. Frontini, S.R. Srinivasan, J.H. Xu, R. Tang, M.G. Bond, and G. Berenson Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study) Am J Cardiol 100 2007 64 68 (Pubitemid 46961899)
47. S.H. Orakzai, K. Nasir, M. Blaha, R.S. Blumenthal, and P. Raggi Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals Atherosclerosis 202 2009 289 295
48. D.L. Rainwater, C.A. McMahan, G.T. Malcom The PDAY Research Group Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects Arterioscler Thromb Vasc Biol 19 1999 753 761 (Pubitemid 29135181)
49. V. Bittner Non-high-density lipoprotein cholesterol and cardiovascular disease Curr Opin Lipidol 14 2003 367 371 (Pubitemid 36951902)
50. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations Can J Cardiol 25 2009 567 579
51. S.M. Grundy Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy Circulation 106 2002 2526 2529 (Pubitemid 35340685)
52. D.S. Freedman, J.D. Otvos, and E.J. Jeyarajah Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study Clin Chem 50 2004 1189 1200 (Pubitemid 38824227)
53. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidology 2 2008 36 42 (Pubitemid 351250867)